Evidence map›Paper›PMID 34987813›Full record

ArticleClinical case reports2021

Successful ruxolitinib administration for a patient with steroid-refractory idiopathic pneumonia syndrome following hematopoietic stem cell transplantation: A case report and literature review.

Dan Tomomasa, Takeshi Isoda, Noriko Mitsuiki, Motoi Yamashita, Aoi Morishita, Takahiro Tomoda, Tsubasa Okano, Akifumi Endo, Takahiro Kamiya, Masakatsu Yanagimachi and 4 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Dan TomomasaDepartment of Pediatrics and Developmental Biology Tokyo Medical and Dental University Tokyo Japan.
Takeshi IsodaDepartment of Pediatrics and Developmental Biology Tokyo Medical and Dental University Tokyo Japan.ORCID https://orcid.org/0000-0003-3349-3705
Noriko MitsuikiDepartment of Pediatrics and Developmental Biology Tokyo Medical and Dental University Tokyo Japan.
Motoi YamashitaDepartment of Pediatrics and Developmental Biology Tokyo Medical and Dental University Tokyo Japan.
Aoi MorishitaDepartment of Pediatrics and Developmental Biology Tokyo Medical and Dental University Tokyo Japan.
Takahiro TomodaDepartment of Pediatrics and Developmental Biology Tokyo Medical and Dental University Tokyo Japan.
Tsubasa OkanoDepartment of Pediatrics and Developmental Biology Tokyo Medical and Dental University Tokyo Japan.
Akifumi EndoClinical Research Center Tokyo Medical and Dental University Tokyo Japan.
Takahiro KamiyaClinical Research Center Tokyo Medical and Dental University Tokyo Japan.
Masakatsu YanagimachiDepartment of Pediatrics and Developmental Biology Tokyo Medical and Dental University Tokyo Japan.
Kohsuke ImaiDepartment of Community Pediatrics, Perinatal and Maternal Medicine Tokyo Medical and Dental University Tokyo Japan.
Hirokazu KaneganeDepartment of Child Health and Development Tokyo Medical and Dental University Tokyo Japan.
Masatoshi TakagiDepartment of Pediatrics and Developmental Biology Tokyo Medical and Dental University Tokyo Japan.ORCID https://orcid.org/0000-0002-7580-9184
Tomohiro MorioDepartment of Pediatrics and Developmental Biology Tokyo Medical and Dental University Tokyo Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Idiopathic pneumonia syndrome (IPS) is an acute lung complication observed after the early posthematopoietic stem cell transplantation (HSCT) period. Ruxolitinib was effective for a patient with myelodysplastic syndrome who developed severe IPS after second HSCT. No severe adverse effects were observed. Ruxolitinib may be an alternative choice for HSCT-related IPS.

Indexed as

graft‐versus‐host diseasehemophagocytic lymphohistiocytosisidiopathic pneumonia syndromemyelodysplastic syndromeruxolitinib

Identifiers

PMID34987813
PMCPMC8693824

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.